Table 1.
Odds ratios for tumor protein expression status of women with diabetes compared to women without diabetes
| Women with breast cancer | ||||
|---|---|---|---|---|
| Independent variable of exposure | ||||
| Diabetes vs. No Diabetes | Diabetes vs. No Diabetes | |||
| Dependent variablea | crude OR (95% CI) | P | adjusted ORb (95% CI) | P |
| p-ER + | 0.84 (0.51–1.37) | 0.48 | 1.03 (0.61–1.73) | 0.92 |
| EGFR + | 1.44 (0.59–3.52) | 0.43 | 1.72 (0.68–4.33) | 0.25 |
| p-ERK 1/2 + | 0.84 (0.52–1.37) | 0.48 | 0.84 (0.51–1.40) | 0.51 |
| p-mTOR + | 0.81 (0.49–1.33) | 0.40 | 0.88 (0.52–1.49) | 0.64 |
| IGF1R + | 0.90 (0.52–1.56) | 0.70 | 0.94 (0.53–1.65) | 0.82 |
aLogistic regression for tumor IHC marker as the dependent variable, with a negative staining of the tumor marker as reference category. bAdjusted for menopause (pre/post) at breast cancer diagnosis and BMI closest measure prior to breast cancer diagnosis (continuous). Women with diabetes were matched on age at breast cancer diagnosis to women without diabetes. p-ER Phosphorylated estrogen receptor, EGFR Epidermal growth = factor receptor, p-ERK Phosphorylated extracellular signal-regulated kinase, p-mTOR Phosphorylated mechanistic target of rapamycin, IGF1R Insulin growth factor 1 receptor, OR Odds Ratio, CI Confidence Interval